GlassScriptPhysician profile
Margaret Phillips
NPI 1326532748
$8,517.86
in general payments reported to CMS, 2019-2025
22 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,104 · 2022: $1,159 · 2023: $2,238 · 2024: $1,867 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,981 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,981.27 |
| Education | $273.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,982.86 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,445.59 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $937.14 | 2022-2025 | |
| Alkermes, INC. | $872.61 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $556.13 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $459.70 | 2021-2025 | Ingrezza |
| Indivior INC. | $451.83 | 2021-2025 | Sublocade, Perseris |
| Axsome Therapeutics, INC. | $394.43 | 2023-2025 | Auvelity |
| Lundbeck LLC | $347.45 | 2021-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $241.40 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Tempus Ai, INC | $168.30 | 2024 | |
| Vanda Pharmaceuticals INC. | $162.33 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $147.64 | 2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $140.53 | 2022-2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $55.60 | 2022-2023 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $35.11 | 2024-2025 | Aptima |
| Braeburn INC. | $27.53 | 2023 | Brixadi |
| Sunovion Pharmaceuticals INC. | $24.58 | 2021 | |
| Noven Therapeutics, LLC | $21.18 | 2023 | Xelstrym |
| Corium, LLC | $16.82 | 2022 | |
| Neos Therapeutics, LP | $14.75 | 2023 | Adzenys Xr-Odt |
| Luye Pharma (USA) LTD. | $14.35 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.